Potential Non-Covalent SARS-CoV-2 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches and Reviewed by Human Medicinal Chemist in Virtual Reality
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
One of the most important SARS-CoV-2 protein targets for therapeutics is the 3C-like protease (main protease, Mpro). In our previous work1we used the first Mpro crystal structure to become available, 6LU7. On February 4, 2020 Insilico Medicine released the first potential novel protease inhibitors designed using a de novo,AI-driven generative chemistry approach. Nearly 100 X-ray structures of Mpro co-crystallized both with covalent and non-covalent ligands have been published since then. Here we utilize the recently published 6W63 crystal structure of Mpro complexed with a non-covalent inhibitor and combined two approaches used in our previous study: ligand-based and crystal structure-based. We published 10 representative structures for potential development with 3D representation in PDB format and welcome medicinal chemists for broad discussion and generated output analysis. The molecules in SDF format and PDB-models for generated protein-ligand complexes are available here and at https://insilico.com/ncov-sprint/.Medicinal chemistry VR analysis was provided by Nanome team and the video of VR session is available at https://bit.ly/ncov-vr.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ChEMBL: a large-scale bioactivity database for drug discovery
Gaulton, A., Bellis, L. J., Bento, A. P., Chambers, J., Davies, M., Hersey, A., Light, Y., McGlinchey, S., Michalovich, D., Al-Lazikani, B., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr777 · Cited by 4,382
SARS and MERS: recent insights into emerging coronaviruses
de Wit, E., van Doremalen, N., Falzarano, D., & Munster, V. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.81 · Cited by 3,510
Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109
Deep learning enables rapid identification of potent DDR1 kinase inhibitors
Zhavoronkov, A., Ivanenkov, Y. A., Aliper, A., Veselov, M. S., Aladinskiy, V. A., Aladinskaya, A. V., Terentiev, V. A., Polykovskiy, D. A., Kuznetsov, M. D., Asadulaev, A., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0224-x · Cited by 1,573
Self-citationAliper, A., Plis, S., Artemov, A., Ulloa, A., Mamoshina, P., & Zhavoronkov, A. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00248 · Cited by 610
Self-citationDrug Development and Medicinal Chemistry Efforts toward SARS‐Coronavirus and Covid‐19 Therapeutics
Ghosh, A. K., Brindisi, M., Shahabi, D., Chapman, M. E., & Mesecar, A. D. (2020) · ChemMedChem · doi:10.1002/cmdc.202000223 · Cited by 306
Entangled Conditional Adversarial Autoencoder for de Novo Drug Discovery
Polykovskiy, D., Zhebrak, A., Vetrov, D., Ivanenkov, Y., Aladinskiy, V., Mamoshina, P., Bozdaganyan, M., Aliper, A., Zhavoronkov, A., & Kadurin, A. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00839 · Cited by 278
Self-citationWill Artificial Intelligence for Drug Discovery Impact Clinical Pharmacology?
Zhavoronkov, A., Vanhaelen, Q., & Oprea, T. I. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1795 · Cited by 159
Self-citation
Cited by
Applications of artificial intelligence in battling against covid-19: A literature review
Tayarani N., M.-H. (2021) · Chaos, Solitons & Fractals · doi:10.1016/j.chaos.2020.110338 · Cited by 210
Unleashing the power of generative AI in drug discovery
Gangwal, A., & Lavecchia, A. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.103992 · Cited by 195
A systematic review on AI/ML approaches against COVID-19 outbreak
Dogan, O., Tiwari, S., Jabbar, M. A., & Guggari, S. (2021) · Complex & Intelligent Systems · doi:10.1007/s40747-021-00424-8 · Cited by 87
Cao, L., & Liu, Q. (2022) · doi:10.1101/2022.08.22.22279022 · Cited by 49
Metadata
- Authors
- Zhavoronkov, A., Zagribelnyy, B., Zhebrak, A., Aladinskiy, V., Terentiev, V., Vanhaelen, Q., Bezrukov, D. S., Polykovskiy, D., Shayakhmetov, R., Filimonov, A., Bishop, M., McCloskey, S., Leija, E., Bright, D., Funakawa, K., Lin, Y.-C., Huang, S.-H., Liao, H.-J., Aliper, A., & Ivanenkov, Y.
- Venue
- ChemRxiv
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-05-19
- ISSN
- 2573-2293 (ISSN-L)
- OpenAlex
- W3089967636
- Cited by
- 44
- References
- 8
- Type
- posted content
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Potential Non-Covalent SARS-CoV-2 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches and Reviewed by Human Medicinal Chemist in Virtual Reality. https://app.cochat.ai/papers/10.26434/chemrxiv.12301457.v1
- The paper
- Zhavoronkov, A., Zagribelnyy, B., Zhebrak, A., Aladinskiy, V., Terentiev, V., Vanhaelen, Q., Bezrukov, D. S., Polykovskiy, D., Shayakhmetov, R., Filimonov, A., Bishop, M., McCloskey, S., Leija, E., Bright, D., Funakawa, K., Lin, Y.-C., Huang, S.-H., Liao, H.-J., Aliper, A., & Ivanenkov, Y. (2020). Potential Non-Covalent SARS-CoV-2 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches and Reviewed by Human Medicinal Chemist in Virtual Reality. ChemRxiv. https://doi.org/10.26434/chemrxiv.12301457.v1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.